Drawing for EBZYVE

USPTO serial 88287993

EBZYVE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
RINGLE, JAMES W
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EBZYVE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bruce W. Longbottom

Bruce W. Longbottom ELI LILLY AND COMPANYLILLY CORPORATE CENTERINDIANAPOLIS, IN 46285UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitisACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 6, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 5, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 1, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 28, 2022EX5GSOU EXTENSION 5 GRANTED—
Feb 28, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 16, 2021EXT5SOU EXTENSION 5 FILED—
Dec 16, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 18, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 16, 2021EX4GSOU EXTENSION 4 GRANTED—
Jun 16, 2021EXT4SOU EXTENSION 4 FILED—
Jun 16, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 2, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 1, 2021EX3GSOU EXTENSION 3 GRANTED—
Jan 11, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 21, 2020EXT3SOU EXTENSION 3 FILED—
Dec 21, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 23, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 19, 2020EX2GSOU EXTENSION 2 GRANTED—
Jun 19, 2020EXT2SOU EXTENSION 2 FILED—
Jun 19, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 13, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 11, 2019EX1GSOU EXTENSION 1 GRANTED—
Dec 11, 2019EXT1SOU EXTENSION 1 FILED—
Dec 11, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 30, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 4, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 4, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 15, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 22, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 16, 2019DOCKASSIGNED TO EXAMINER—
Feb 26, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 7, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance